EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte Studie

Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study

Elena A Christofides, Orlando Puente, Paul Norwood, Douglas Denham, Hiralal Maheshwari, Michael Lillestol, Terence Hart, Samer Nakhle, Anurekha Chadha, David Fitz-Patrick, Danny Sugimoto iD, Joseph Soufer und 10 weitere

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15560 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Elena A Christofides und 21 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Research Associates, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Gan & Lee Pharmaceuticals Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate the equivalence of immunogenicity, safety and efficacy of Gan & Lee (GL) Glargine (Basalin®; Gan & Lee Pharmaceutical) with that of the reference product (Lantus®) in adult participants with type 2 diabetes mellitus.

Methods

This was a phase 3, multicenter, open‐label, equivalence trial conducted across 57 sites. In total, 567 participants with type 2 diabetes mellitus were randomized in a 1:1 ratio to undergo treatment with either GL Glargine or Lantus® for 26 weeks. The primary endpoint was the proportion of participants in each treatment arm who manifested treatment‐induced anti‐insulin antibodies (AIA). Secondary endpoints included efficacy and safety metrics, changes in glycated haemoglobin levels, and a comparative assessment of adverse events. Results were analysed using an equivalence test comparing the limits of the 90% confidence interval (CI) for treatment‐induced AIA development to the prespecified margins.

Results

The percentages of participants positive for treatment‐induced glycated haemoglobin by week 26 were similar between the GL Glargine (19.2%) and Lantus® (21.3%) treatment groups, with a treatment difference of −2.1 percentage points and a 90% CI (−7.6%, 3.5%) (predefined similarity margins: −10.7%, 10.7%). The difference in glycated haemoglobin was −0.08% (90% CI, −0.23, 0.06). The overall percentage of participants with any treatment‐emergent adverse events was similar between the GL Glargine (80.1%) and Lantus® (81.6%) treatment groups.

Conclusions

GL Glargine was similar to Lantus® in terms of immunogenicity, efficacy, and safety, based on the current study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsDiabetes Mellitus, Type 2Glycated HemoglobinHypoglycemic AgentsInsulin GlargineAdultAgedFemaleHumansMaleMiddle AgedBlood GlucoseHypoglycemiaInsulin AntibodiesTherapeutic EquivalencyTreatment Outcome

Stichwörter der Autor:innen

biosimilarimmunogenicityinsulin glarginetype 2 diabetes mellitus

Substanzen

Biosimilar PharmaceuticalsBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulin AntibodiesInsulin Glargine

Autor:innen und Institutionen

  • Endocrinology Research Associates, Columbus, Ohio, USA.
  • Miami Dade Medical Research Institute, Miami, Florida, USA.
  • Valley Research, Fresno, California, USA.
  • Clinical Trials of Texas, San Antonio, Texas, USA.
  • Midwest CRC, Crystal Lake, Illinois, USA.
  • Lillestol Research, Fargo, North Dakota, USA.

ORCID-Profile: Danny Sugimoto, Mark Warren

Förderung

  • Gan & Lee Pharmaceuticals Co., Ltd

Zitieren

APA

Christofides, E. A., Puente, O., Norwood, P., Denham, D., Maheshwari, H., Lillestol, M., Hart, T., Nakhle, S., Chadha, A., Fitz-Patrick, D., Sugimoto, D., Soufer, J., Young, D., Warren, M., Huffman, D., Reed, J., Bays, H., Arora, S., Rizzardi, B., …, & Johnson, K. A. (2024). Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15560

Vancouver

Christofides EA, Puente O, Norwood P, Denham D, Maheshwari H, Lillestol M, et al. Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15560

BibTeX
@article{Christofides2024,
  author = {Christofides, Elena A and Puente, Orlando and Norwood, Paul and Denham, Douglas and Maheshwari, Hiralal and Lillestol, Michael and Hart, Terence and Nakhle, Samer and Chadha, Anurekha and Fitz-Patrick, David and Sugimoto, Danny and Soufer, Joseph and Young, Douglas and Warren, Mark and Huffman, David and Reed, John and Bays, Harold and Arora, Samir and Rizzardi, Barbara and Tidman, Raymond and Rendell, Marc and Johnson, Kimball A},
  title = {Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15560}
}
Kostenlos starten →